Eras­ing can­cer, re­viv­ing on­colyt­ic virus, treat­ing a rare neu­ro­mus­cu­lar con­di­tion: Here's what you need to know about the 5 new biotechs fil­ing for IPOs

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Last week was a busy one for biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.